KaloBios Inc.
This article was originally published in Start Up
Executive Summary
A handful of companies control the intellectual property for and offer access to human antibody discovery and engineering capabilities. KaloBios thinks it will be one of them, having built a platform of proprietary in vitro technologies for creating and optimizing human antibodies. To fully leverage the value of its technology platform, the start-up is becoming vertically integrated, via a merger with Celscia Therapeutics, which will give it the capability to not only discover and engineer clinically relevant antibodies, but also to develop them and bring them through to the clinic quickly.
You may also be interested in...
What Keeps Cancer Drug Developers Awake at Night
The range of comments, as well as the general tone, of a recent clinical cancer meeting prompted us to ask developers of cancer drugs what they saw as the major issues and hurdles in designing and testing new compounds. Their comments suggest that empirical methodologies, albeit informed by understanding of the biology around a target, will dominate clinical thinking in the near term. Clinical setbacks over the past several years, a lack of validated biomarkers, and an awareness that preclinical models are of limited utility in establishing dose and identifying likely responders, have reinforced that perception. Developers' principal concerns therefore often focus on things that are within their control; in particular, how to resource and manage a program for the long haul.
What Keeps Cancer Drug Developers Awake at Night
The range of comments, as well as the general tone, of a recent clinical cancer meeting prompted us to ask developers of cancer drugs what they saw as the major issues and hurdles in designing and testing new compounds. Their comments suggest that empirical methodologies, albeit informed by understanding of the biology around a target, will dominate clinical thinking in the near term. Clinical setbacks over the past several years, a lack of validated biomarkers, and an awareness that preclinical models are of limited utility in establishing dose and identifying likely responders, have reinforced that perception. Developers' principal concerns therefore often focus on things that are within their control; in particular, how to resource and manage a program for the long haul.
Therapeutic Antibody Start-Ups
After more than a decade of anticipation, pharmas have now clearly recognized the value of antibodies as therapeutics. And biotechs can offer discovery tools and development expertise.